

Scientists welcomed the news but expressed caution, noting two recent randomized controlled trials didn't show benefits in patients treated with tocilizumab. However, one other trial, published in JAMA recently, did.

“Results on the use of [steroids](#) in severe COVID have provided proof of principle that anti-inflammatory drug can help, so this is an encouraging result which suggests that other, more targeted, anti-inflammatory drugs may also help,” said [5.1.2e](#), [5.1.2e](#) University of Oxford. But he noted overall that study results have been mixed.

“It is likely that tocilizumab will benefit some patients,” said [5.1.2e](#) [5.1.2e](#) [5.1.2e](#) University of Bristol. “What is still not clear is how we identify the patient population with COVID-19 which is likely to benefit from tocilizumab.”

Related stories on these topics: [Clinical trials](#), [Coronavirus](#), [Drug and device safety](#), [Hospitals](#), [Infectious diseases](#), [Medicines](#), [Patients](#), [Pharma](#), [Regulation](#), [Matt Hancock](#), [U.K. National Health Service \(NHS\)](#)

To update your POLITICO Pro notification preferences, visit www.politico.eu/notification

** Tell us what you think: Was this Pro content helpful? [Yes](#) | [No](#) **

View the Pro calendar at www.politico.eu/calendar. Submit an event [here](#).

This email alert has been sent for your exclusive use as a POLITICO Pro subscriber. Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of the POLITICO Pro license agreement.

This email was sent to [5.1.2e](#) [@minvws.nl](mailto:5.1.2e@minvws.nl)
[Adjust your Pro subscription settings](#), or
[unsubscribe from all POLITICO SRL emails](#)
POLITICO SRL · Rue de la Loi 62 · Brussels 1040 · Belgium